several clinical studies were performed on clofibrate as monotherapy or in combination with androsterone. These trials showed that clofibrate decreases lipid levels in hypercholesterolemic patients, mainly as the result of a reduction in the very low density lipoprotein (VLDL), and less in the low density lipoprotein (LDL) fraction, that it was well tolerated in long-term treatment and that the coadministration of androsterone was not necessary for its hypolipidemic effect , . However, the mode of action of clofibrate was still 7 8
unclear and 30 years of intensive research was needed to discover it. Researchers were worried by the fact that long-term treatment with clofibrate induces hepatomegaly in rats as the result of unexplained proliferation of hepatic cytoplasmic inclusion bodies called peroxisomes . Nevertheless, clofibrate was approved in the United States in 1967 for the treatment of hyperlipidemias. Further studies 9
suggested that the peroxisome proliferation and the hypolipidemic properties of clofibrate were independent , , but the mechanism 10 11 was not known. Several years later, two other hypolipidemic compounds, Wy-14,653 and tibric acid, were found to be more potent than clofibrate in increasing peroxisome proliferation in livers of rats and mice, despite being structurally different from clofibrate and the other oxyisobutyric acid derivatives . 12
Disturbed by concerns about the clofibrate-induced hepatomegaly in murine species, Thorp and colleagues tried to modify the clofibrate structure to identify more potent hypolipidemic fibrate drugs with minimum toxicity. To do so, they used a test measuring the displacement of albumin-bound L-thyroxin because they thought that clofibrate exhibited indirect hypocholesterolemic activities because of its capacity to bind to albumin and displace albumin-bound proteins such as L-thyroxin. Two analogs were selected: methyl-clofenapate and clobuzarit. Despite higher-potency and lipid-lowering activity when compared with clofibrate, methyl-clofenapate was withdrawn from clinical studies not only because of the induction of strong hepatomegaly and peroxisome proliferation in rats, but also because of the occurence of hepatic carcinomas in rats that, at that time, were thought to be prognostic for humans. Clobuzarit was less hypolipidemic than clofibrate; however, it induced a significant decrease in plasma fibrinogen levels and was oriented toward the treatment of rheumatoid arthritis due to its anti-inflammatory properties.
Meanwhile, several pharmaceutical companies performed intensive research to improve the pharmacological and pharmacokinetic activities of clofibrate. Many modifications were tested: the phenoxy-2-methyl-2-propionic acid chain of clofibrate was preserved and the Cl atom was substituted by different hydrophobic groups. However, none of the obtained phenylketone molecules were interesting hypolipidemic drugs, except for the benzoyl derivative with a Cl atom in position 4, which was called procetofen. 
Discovery of the glitazones
Thiazolidinediones (TZD), also termed glitazones, are widely prescribed in the treatment of type 2 diabetes as monotherapy or in combination with sulfonylureas, metformin, dipeptidyl peptidase-4 inhibitors and insulin. However, their discovery, in the early 1980s, was quite surprising when Japanese researchers tried to synthesize more potent fibrate hypolipidemic drugs. Indeed, in 1975, Takeda laboratories in Japan synthesized 71 analogues of clofibrate, i.e. alkanoic acids containing a biphenyl ether moiety, and tested them for hypolipidemic properties. Interestingly, some of these compounds showed both hypolipidemic and hypoglycemic effects in diabetic mice , . Thus, extensive structure-activities relationship studies led to the discovery of ADD-3878, also called ciglitazone , , which 21 22 23 24 was shown to normalize hyperglycemia, hyperinsulinemia and hypertriglyceridemia in animal models of type 2 diabetes without provoking hypoglycemia . Consecutively, another glitazone, troglitazone (CS-045), discovered by Sankyo Company in 1988 , 25 26 decreased insulin resistance by both increasing insulin-stimulated glucose utilization and reducing hepatic glucose production. Troglitazone was the first TZD approved for clinical use in the United States in 1997; unfortunately, it was subsequently withdrawn worldwide because of liver toxicity . Meanwhile, an intensive insulin resistance targeted drug research program had been initiated by 27
SmithKline in the United Kingdom to develop insulin sensitizers more potent than ciglitazone. BRL-49653, synthesized in 1988 and later known as rosiglitazone, was shown to normalize blood glucose levels and to improve tissue sensitivity in rodent models and in patients with type 2 diabetes, to be orally active, and to be more selective and more potent (1 mg/kg) than ciglitazone (150 mg/kg) , . In 28 29 parallel, Takeda laboratories in Japan developed another TZD compound, pioglitazone (AD-4833) , which also ameliorates glucose and 30 lipid profiles in patients with type 2 diabetes. Rosiglitazone and pioglitazone were approved in the United States in 1999 for the treatment of type 2 diabetes; today, they represent the only two glitazones used in the treatment of type 2 diabetes.
Fibrates, glitazones and PPARs: from classic to molecular pharmacology PPAR and fibrate action α
In the mid-1980s, Reddy et al showed that fibrates increase the transcription of peroxisomal fatty acid -oxidation genes in liver rat , β 31 whereas our studies in Leuven, Belgium, at the end of the 1980s showed that fibrates regulate the expression of genes involved in lipoprotein metabolism . The triggering event in the understanding of fibrate action occured in 1990 when two researchers from the 32
Central Toxicology Laboratories of ICI, Isseman and Green, identified a novel member of the steroid hormone receptor superfamily of ligand-activated transcription factors. The receptor was structurally related but clearly different from steroid hormone receptors, could be activated by a wide range of molecules including several fatty acids and the pharmacological class of fibrates, was thought to mediate the peroxisome proliferation response and was, therefore, called Peroxisome Proliferator-Activated Receptor (PPAR), later PPAR 33 α (NR1C1). This receptor was expressed at a high level in the liver, kidney and heart. Further studies showed that PPAR activation increases the transcription of specific PPAR target genes after heterodimerization with the Retinoid X Receptor (RXR), and binding of the complex to specific transcriptional regulatory elements called Peroxisome Proliferator Response Elements (PPREs) , . It was hypothesized that Page / 3 6 the hypolipidemic effects of fibrates were mediated through PPAR , which was proven by using knockout (KO) mouse models that α36 allow the study of the role of this receptor. Thus, using the PPAR KO mouse , it was shown that fibrates decrease plasma lipid in vivo α 37 levels and induce hepatomegaly and hepatic peroxisome proliferation in a PPAR -dependent manner. Moreover, species differences in α PPAR function, particularly between murine species and humans, were found at the level of PPAR expression, ligand activation and α α biological responses, especially with respect to its role in peroxisome proliferation in rats and mice, but not humans . 38
By using molecular biology and functional genomic technologies, target genes of PPAR were identified with roles not only in lipid α homeostasis but also in other pathways. Thus, in humans, the increase in serum high density lipoprotein-cholesterol (HDL-C)
concentrations is related to the gene activation of two major HDL apolipoproteins (apo), apoA-I and apoA-II, by PPAR . Moreover, the α39 TG-lowering action of fibrates, related to decreased synthesis and increased catabolism of VLDL, was associated with the inhibition of apo C-III expression, a well-known inhibitor of lipoprotein lipase (LPL), and the induction of LPL and apoA-V expression. In addition to its major role in lipid homeostasis, PPAR has exhibited additional pleiotropic effects on endothelial dysfunction, myocardial ischemic injury α and immune-inflammatory responses. At that time, PPAR was found to be expressed in the major cell types of the atherosclerotic plaque α including macrophages, smooth muscle cells, endothelial cells and lymphocytes; its activation resulted in direct antiatherogenic effects in the artery wall . PPAR activation reduces the recruitment and adhesion of mononuclear cells to the endothelium, decreases 40 α atherosclerotic plaque inflammation and proliferation of smooth muscle cells, and facilitates cholesterol efflux by increasing the expression of the transporters scavenger receptor-BI and ATP-binding cassette transporter A-1 in macrophages. Thus, these molecular actions of PPAR increased our understanding of the hypolipemic effects of fibrates and suggested an interesting potential of these drugs α in the control of cardiovascular disease and its risk factors.
PPAR and glitazone action γ
After the discovery of PPAR in 1990, two other genes belonging to the same family, PPAR / (NR1C2) and PPAR (NR1C3), were The discovery of the role of the PPARs in the regulation of lipid and glucose metabolism led the pharmaceutical industry to develop PPAR coagonists. Because many patients with insulin resistance also exhibit dyslipidemia, it was theoretically judicious to create dual PPAR / agonists to treat these patients. Indeed, these dual PPAR /PPAR agonists, also named glitazars, combine the insulin sensitizing 
Selective PPAR modulators (SPPARMs)
Resulting from a better understanding of the molecular actions of nuclear receptors, the concept of selective PPAR modulators (SPPARMs), in analogy to selective estrogen receptor modulators (SERMs), emerged recently as a means to optimize the therapeutic potential. This new molecular-target based strategy aims to synthesize PPAR agonist with a target-oriented therapeutic profile, maintaining the desired therapeutic benefit and minimizing the adverse effects of the first-generation PPAR agonists. At the molecular level, each PPAR ligand induces a specific change in PPAR conformation, resulting in the differential recruitment of cofactors and gene-specific transcriptional regulation. Thus, in addition to a panel of common genes regulated in a similar manner by all agonists, each agonist also induces its proper profile of genes, resulting in specific biological effects. The validity of the concept is clinically supported by observations that fenofibrate and gemfibrozil, which both increase HDL-C levels, have distinct effects on human apoA-I concentrations.
Thus, new compounds were created with differential gene-regulating properties. This concept of SPPARMs is also particularly relevant for PPAR agonists. Indeed, because rosiglitazone and pioglitazone display well-documented adverse effects such as body weight gain, γ increased risk for bone fractures, and edema, the idea is to develop compounds retaining the beneficial effects of these full PPAR agonists γ on glucose metabolism without the adverse effects. Several TZD-like and non-TZD-like PPAR partial agonists or SPPAR Ms have been γ γ synthesised and some of them have entered clinical studies such as halofenate/metaglidasen, DRF-2593 (balaglitazone) or MCC555 (netoglitazone).
Conclusions
Fibrates and TZDs were developed decades ago for the treatment of dyslipidemia and type 2 diabetes. However, since 1990, their mechanism, through the discovery of the PPARs, began to be elucidated. Since that time, PPARs have been shown to be implicated in many processes such as lipid and glucose metabolism, inflammation or cardiovascular functions, thus presenting PPARs as interesting pharmacological targets. In addition, the use of PPAR ligands enabled advancements regarding the physiological roles of PPARs.
Although none of the new synthetic PPAR agonists, PPAR coagonists or selective PPAR modulators, have replaced the first-generation fibrates and TZDs, they constitute a panel of promising drug. We are sure that PPARs have not revealed all their secrets and will continue to interest researchers who are trying to understand their physiological roles and their potential as targets for drugs to prevent cardiometabolic disorders.
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